Investing in one of the world’s most promising true treatments for chronic stroke
Reach Neuro is pioneering the world’s first true treatment for chronic stroke, capable of directly restoring a person’s ability to control their own movement. Using targeted neuromodulation and AI, Reach Neuro personalizes the therapy for each patient and maximizes clinical outcomes.
METIS’s investment is being used to support a chronic clinical study that will use Reach Neuro's therapy in combination with physical rehabilitation to learn how best to optimize the treatment to maximize outcomes and to push the technology one step further toward the clinic.
METIS represents the customer — the clinicians who work with stroke patients every day. As such, we understand the need Reach Neuro is solving, we have seen and treated countless patients who survived their stroke, but never recovered their independence, and are looking for any other options to move forward.
1 in 8 people will become permanently disabled because of a stroke during their life. Nearly everyone has been or will be affected by it in some way. Reach Neuro's therapy has the potential to help millions of people, changing the way we think about post-stroke recovery.
During early clinical work, Reach Neuro helped patients regain their ability to feed themselves, perform chores around the house, manipulate everyday objects, and achieve greater independence.
Reach Neuro targets the spinal cord, where the neurons for movement of the shoulder, arm, and hand reside.
An electrode array is implanted in the cervical spinal cord. The implanted pulse generator delivers a personalized stimulation protocol. Small electrical pulses are precisely delivered to re-awaken the nervous system giving stoke patients back control of their arm.
Reach Neuro's therapy is custom tuned, ensuring that the optimal stimulation is delivered for each patient.
Reach Neuro is poised to change the standard of care for post-acute stroke recovery. When successful, it will also become the largest neuromodulation market, with a patient population larger than all other neuromodulation treatments combined.
